{
    "clinical_study": {
        "@rank": "90632", 
        "arm_group": [
            {
                "arm_group_label": "Placebo CPAP", 
                "arm_group_type": "Placebo Comparator", 
                "description": "patients established on CPAP therapy, who are randomized to the placebo comparator, will use a CPAP device with subtherapeutic pressure during two weeks."
            }, 
            {
                "arm_group_label": "therapeutic CPAP", 
                "arm_group_type": "Active Comparator", 
                "description": "patients who are randomized to the active comparator, will continue with CPAP treatment with therapeutic pressure during two weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Randomized controlled trial (therapeutic vs. placebo CPAP) including 46  patients with\n      obstructive sleep apnea (OSA) to define the physiological effects of continuous positive\n      airway pressure (CPAP) therapy withdrawal on myocardial perfusion and dermal and renal\n      microvascular function during a 2 week period."
        }, 
        "brief_title": "Randomized-controlled Trial (RCT) on CPAP-withdrawal and Microvascular Function in OSA", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Obstructive Sleep Apnoea", 
        "condition_browse": {
            "mesh_term": [
                "Apnea", 
                "Sleep Apnea Syndromes", 
                "Sleep Apnea, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Objectively confirmed OSA (at the time of original diagnosis) with an oxygen\n             desaturation index (ODI, =4% dips) of >20/h and an ESS of >10.\n\n          -  Currently >20/h oxygen desaturations (=4% dips) during an ambulatory nocturnal pulse\n             oximetry performed at the end of a 4-night period without CPAP.\n\n          -  Treated with CPAP for more than 12 months, minimum compliance 4h per night, AHI<10\n             with treatment (according to CPAP machine download data).\n\n          -  Current ESS <10.\n\n        Exclusion criteria:\n\n          -  Previous ventilatory failure (awake SpO2 <93% and PaCO2>6kPa).\n\n          -  Unstable, untreated coronary or peripheral artery disease, severe arterial\n             hypertension or hypotension  (>180/110 or <90/60mmHg)\n\n          -  Previously diagnosed with Cheyne-Stokes breathing.\n\n          -  Current professional driver; Any previous sleep related accident.\n\n          -  Age <20 or >75 years at trial entry.\n\n          -  Acute inflammatory disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797653", 
            "org_study_id": "CPAP_V1.0 (01.11.2012)"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo CPAP", 
                "description": "CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks", 
                "intervention_name": "CPAP therapy withdrawal", 
                "intervention_type": "Other", 
                "other_name": "CPAP treatment with subtherapeutic pressure"
            }, 
            {
                "arm_group_label": "therapeutic CPAP", 
                "description": "Continue treatment with therapeutic continuous positive airway pressure device", 
                "intervention_name": "Continue CPAP treatment", 
                "intervention_type": "Procedure", 
                "other_name": "therapeutic continuous positive airway pressure device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "state": "ZH", 
                    "zip": "8091"
                }, 
                "name": "University Hospital Zurich, Division of Pneumology"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of CPAP-withdrawal on Microvascular Function in Patients With Obstructive Sleep Apnea: A Randomized-controlled Trial", 
        "overall_official": {
            "affiliation": "University Hospital Zurich, Division of Pneumology", 
            "last_name": "Malcolm Kohler, Prof MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Ethikkommission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "hyperaemic myocardial blood flow", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797653"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Coronary flow reserve determined by PET", 
                "measure": "Coronary flow reserve", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Urine albumine excretion rate", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Dermal microvascular vasodilatory response", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }
        ], 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}